149 related articles for article (PubMed ID: 36687766)
1. Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor.
Ton C; Stabile V; Carey E; Maraikar A; Whitmer T; Marrone S; Afanador NL; Zabrodin I; Manomohan G; Whiteman M; Hofmann C
Biotechnol Rep (Amst); 2023 Mar; 37():e00782. PubMed ID: 36687766
[TBL] [Abstract][Full Text] [Related]
2. High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors.
Todesco HM; Gafuik C; John CM; Roberts EL; Borys BS; Pawluk A; Kallos MS; Potts KG; Mahoney DJ
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101189. PubMed ID: 38327804
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.
Robbins JA; Tait D; Huang Q; Dubey S; Crumley T; Cote J; Luk J; Sachs JR; Rutkowski K; Park H; Schwab R; Howitt WJ; Rondon JC; Hernandez-Illas M; O'Reilly T; Smith W; Simon J; Hardalo C; Zhao X; Wnek R; Cope A; Lai E; Annunziato P; Guris D; Stoch SA
EBioMedicine; 2022 Aug; 82():104138. PubMed ID: 35809371
[TBL] [Abstract][Full Text] [Related]
4. Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel
Cohen N; Simon I; Hazan O; Tal A; Tzadok H; Levin L; Girshengorn M; Mimran LC; Natan N; Baruhi T; David AB; Rosen O; Shmaya S; Borni S; Cohen N; Lupu E; Kedmi A; Zilberman O; Jayson A; Monash A; Dor E; Diamant E; Goldvaser M; Cohen-Gihon I; Israeli O; Lazar S; Shifman O; Beth-Din A; Zvi A; Oren Z; Makovitzki A; Lerer E; Mimran A; Toister E; Zichel R; Adar Y; Epstein E
Front Bioeng Biotechnol; 2024; 12():1333548. PubMed ID: 38449674
[TBL] [Abstract][Full Text] [Related]
5. Optimization of VSV-ΔG-spike production process with the Ambr15 system for a SARS-COV-2 vaccine.
Rosen O; Jayson A; Goldvaser M; Dor E; Monash A; Levin L; Cherry L; Lupu E; Natan N; Girshengorn M; Epstein E
Biotechnol Bioeng; 2022 Jul; 119(7):1839-1848. PubMed ID: 35319097
[TBL] [Abstract][Full Text] [Related]
6. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
Kiesslich S; Kim GN; Shen CF; Kang CY; Kamen AA
Biotechnol Bioeng; 2021 Jul; 118(7):2649-2659. PubMed ID: 33837958
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots.
Gillespie PF; Wang Y; Hofmann C; Kuczynski LE; Winters MA; Teyral JL; Tubbs CM; Shiflett K; Patel N; Rustandi RR
ACS Omega; 2023 Jan; 8(3):3319-3328. PubMed ID: 36685032
[TBL] [Abstract][Full Text] [Related]
8. Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.
Kiesslich S; Vila-Chã Losa JP; Gélinas JF; Kamen AA
J Biotechnol; 2020 Feb; 310():32-39. PubMed ID: 32006630
[TBL] [Abstract][Full Text] [Related]
9. Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine.
Yang Z; Paes BCMF; Fulber JPC; Tran MY; Farnós O; Kamen AA
Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112753
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of a Plaque Assay to Determine the Titer of a Recombinant Live-Attenuated Viral Vaccine for SARS-CoV-2.
Toister E; Cherry L; Lupu E; Monash A; Dor E; Levin L; Girshengorn M; Natan N; Chapman S; Shmaya S; Epstein E; Adar Y; Zichel R; Ophir Y; Diamant E
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675756
[TBL] [Abstract][Full Text] [Related]
11. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
[TBL] [Abstract][Full Text] [Related]
12. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL
EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046
[TBL] [Abstract][Full Text] [Related]
13. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor.
Rourou S; van der Ark A; Majoul S; Trabelsi K; van der Velden T; Kallel H
Appl Microbiol Biotechnol; 2009 Nov; 85(1):53-63. PubMed ID: 19521697
[TBL] [Abstract][Full Text] [Related]
14. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
[TBL] [Abstract][Full Text] [Related]
15. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
Kim GN; Choi JA; Wu K; Saeedian N; Yang E; Park H; Woo SJ; Lim G; Kim SG; Eo SK; Jeong HW; Kim T; Chang JH; Seo SH; Kim NH; Choi E; Choo S; Lee S; Winterborn A; Li Y; Parham K; Donovan JM; Fenton B; Dikeakos JD; Dekaban GA; Haeryfar SMM; Troyer RM; Arts EJ; Barr SD; Song M; Kang CY
PLoS Pathog; 2021 Dec; 17(12):e1010092. PubMed ID: 34914812
[TBL] [Abstract][Full Text] [Related]
16. Application of Ambr15 system for simulation of entire SARS-CoV-2 vaccine production process involving macrocarriers.
Jayson A; Goldvaser M; Dor E; Monash A; Levin L; Cherry L; Lupu E; Natan N; Girshengorn M; Epstein E; Rosen O
Biotechnol Prog; 2022 Sep; 38(5):e3277. PubMed ID: 35633106
[TBL] [Abstract][Full Text] [Related]
17. Production of reovirus type-1 and type-3 from Vero cells grown on solid and macroporous microcarriers.
Berry JM; Barnabé N; Coombs KM; Butler M
Biotechnol Bioeng; 1999 Jan; 62(1):12-9. PubMed ID: 10099508
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor.
Offersgaard A; Duarte Hernandez CR; Pihl AF; Costa R; Venkatesan NP; Lin X; Van Pham L; Feng S; Fahnøe U; Scheel TKH; Ramirez S; Reichl U; Bukh J; Genzel Y; Gottwein JM
Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34209694
[TBL] [Abstract][Full Text] [Related]
19. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media.
Genzel Y; Olmer RM; Schäfer B; Reichl U
Vaccine; 2006 Aug; 24(35-36):6074-87. PubMed ID: 16781022
[TBL] [Abstract][Full Text] [Related]
20. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions.
Rourou S; van der Ark A; van der Velden T; Kallel H
Vaccine; 2007 May; 25(19):3879-89. PubMed ID: 17307281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
